In a phase II trial of lenvantinib, there was no difference in treatment response according to RET mutation status; however, high baseline levels of VEGF correlated with greater tumor shrinkage, and low levels of ANG2, sTie-2, HGF, and interleukin (IL)-8 were associated with tumor shrinkage and prolonged PFS (75). The gene discussed is CXCL8; the disease is neoplasm.